Apr 13, 2021 / 01:30PM GMT
Chad Jason Messer - Needham & Company, LLC, Research Division - Senior Analyst
All right. Hello, everybody. Thanks for joining us at the Needham Virtual Health Care Conference. My name is Chad Messer. I'm a senior biotech analyst here at Needham & Company. It is my pleasure to be speaking today with Tim Mayleben, CEO of Esperion, to discuss progress at the company. And I think we're just going to jump right into it.
So good morning, Tim. I really want to start by congratulating Esperion for your execution over the last year. I mean we're in a global pandemic, but you guys launched 2 drugs. You delivered a Japanese deal, debt financing. How have you guys managed so well in this challenging environment?
Timothy M. Mayleben - Esperion Therapeutics, Inc. - President, CEO & Director
Well, Chad, so first off, I just want to thank you for -- well, for you and your colleagues here at Needham for hosting us today. As you highlighted, 2020 was not the year any of us expected it to be. But I think one thing that has driven us for, well, most of the
Esperion Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 13, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers